
TLX Stock Forecast & Price Target
TLX Analyst Ratings
Bulls say
Telix Pharmaceuticals is expected to outperform in the market with a $22 PT due to its strong pipeline of potential radiopharmaceuticals, most notably TLX591/592, and a current revenue source from US sales of Illuccix. Risks to this positive outlook include potential clinical and regulatory failures of its pipeline programs and potential delays in obtaining regulatory approvals. The valuation is based on a blended peer group multiple to projected sales in 2026 and a sum-of-parts valuation for its pipeline programs, with some risk-adjustments applied.
Bears say
Telix Pharmaceuticals is facing potential headwinds in revenue generation as their main product, Illuccix, is an imaging agent rather than a therapeutic agent. While their recent collaboration with Regeneron Pharmaceuticals may provide external validation of their R&D platform, the success of their pipeline drugs is still uncertain. The company also faces financial risks with the potential for upfront payments and milestones from the collaboration not materializing. Investors should exercise caution when considering this stock.
This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares